📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Oncogenic EP300 can be targeted with inhibitors of aldo-keto reductases (2019)

First Author: Mahmud Z

Attributed to: Targeting the FOXM1 signature for early diagnosis and treatment in cholangiocarcinoma funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.bcp.2019.03.009

PubMed Identifier: 30862505

Publication URI: http://europepmc.org/abstract/MED/30862505

Type: Journal Article/Review

Parent Publication: Biochemical Pharmacology

ISSN: 0006-2952